search
Back to results

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

Primary Purpose

KRAS G12C

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
GFH925
Sponsored by
Innovent Biologics (Suzhou) Co. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for KRAS G12C

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men or women ≥18 years old
  • Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation
  • Adequate organ function
  • Measurable disease per RECIST 1.1 criteria.

Exclusion Criteria:

  • Significant concomitant diseases
  • Active brain metastases
  • Previous treatment with KRAS G12C inhibitor.

Sites / Locations

  • Guangdong Provincial People's HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

GFH925

Arm Description

Phase Ia Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design. Phase Ia Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently. Phase Ib Subjects with KRAS G12C mutant advanced colorectal cancer or other tumors will be enrolled and treated at the monotherapy RP2D to evaluate the efficacy. Phase 2 Subjects with KRAS G12C mutant advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy.

Outcomes

Primary Outcome Measures

Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); changes in laboratory tests, vital signs, physical examinations, electrocardiograms (ECGs)
Safety measures
Phase Ia: Incidence of dose-limiting toxicity (DLT) events
Safety measures
Phase Ib: ORR per RECIST 1.1
Efficacy measures
Phase II: ORR assessed by Independent Radiographic Review Committee (IRRC) according to RECIST 1.1
Efficacy measures

Secondary Outcome Measures

Phase Ia: PK parameters of GFH925 include but are not limited to: Cmax, Tmax, AUC, t1/2, CL/F and Vd/F
Efficacy measures and safety measures
Phase Ia: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS),Overall survival (OS)
Efficacy measures
Phase Ib and Phase II: DCR, DoR, TTR, PFS per RECIST 1.1, progression-free survival rate at 6 and 12 months, overall survival rate at 12 months
Efficacy measures
Phase Ib and Phase II: Incidence and severity of AEs, SAEs, AEs leading to treatment interruption, and AEs leading to treatment discontinuation of GFH925 monotherapy
Safety measures
Phase Ib and Phase II: Plasma concentration (including Ctrough) after multiple dose administration in subjects
Efficacy measures and safety measures

Full Information

First Posted
August 8, 2021
Last Updated
August 13, 2023
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05005234
Brief Title
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Official Title
An Open-label, Multi-center Phase I/II Clinical Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Effectiveness of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 10, 2021 (Actual)
Primary Completion Date
January 10, 2024 (Anticipated)
Study Completion Date
April 10, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innovent Biologics (Suzhou) Co. Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Phase Ia: To evaluate the safety/tolerability of GFH925 in subjects with KRAS G12C-mutated advanced solid tumors; To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of GFH925. Phase Ib: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced colorectal cancer or other tumors. Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C mutant advanced non-small cell lung cancer (NSCLC).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
KRAS G12C

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
264 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
GFH925
Arm Type
Experimental
Arm Description
Phase Ia Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design. Phase Ia Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently. Phase Ib Subjects with KRAS G12C mutant advanced colorectal cancer or other tumors will be enrolled and treated at the monotherapy RP2D to evaluate the efficacy. Phase 2 Subjects with KRAS G12C mutant advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy.
Intervention Type
Drug
Intervention Name(s)
GFH925
Intervention Description
Administered as an oral tablet formulation
Primary Outcome Measure Information:
Title
Phase Ia: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs); changes in laboratory tests, vital signs, physical examinations, electrocardiograms (ECGs)
Description
Safety measures
Time Frame
Baseline to 24 Months
Title
Phase Ia: Incidence of dose-limiting toxicity (DLT) events
Description
Safety measures
Time Frame
At the end of Cycle 1(each cycle is 21 days)
Title
Phase Ib: ORR per RECIST 1.1
Description
Efficacy measures
Time Frame
Continuous evaluation during treatment
Title
Phase II: ORR assessed by Independent Radiographic Review Committee (IRRC) according to RECIST 1.1
Description
Efficacy measures
Time Frame
Continuous evaluation during treatment
Secondary Outcome Measure Information:
Title
Phase Ia: PK parameters of GFH925 include but are not limited to: Cmax, Tmax, AUC, t1/2, CL/F and Vd/F
Description
Efficacy measures and safety measures
Time Frame
To complete 3 treatments cycles(each cycle is 21 days)
Title
Phase Ia: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS),Overall survival (OS)
Description
Efficacy measures
Time Frame
Continuous evaluation during treatment
Title
Phase Ib and Phase II: DCR, DoR, TTR, PFS per RECIST 1.1, progression-free survival rate at 6 and 12 months, overall survival rate at 12 months
Description
Efficacy measures
Time Frame
Continuous evaluation during treatment
Title
Phase Ib and Phase II: Incidence and severity of AEs, SAEs, AEs leading to treatment interruption, and AEs leading to treatment discontinuation of GFH925 monotherapy
Description
Safety measures
Time Frame
Baseline to 24 Months
Title
Phase Ib and Phase II: Plasma concentration (including Ctrough) after multiple dose administration in subjects
Description
Efficacy measures and safety measures
Time Frame
To complete 3 treatments cycles(each cycle is 21 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Volunteer to participate in the study and sign the informed consent form. Aged 18 years or older at the time of signing the informed consent form. Subjects must have one measurable lesion (per RECIST 1.1). Subjects with toxic reaction caused by prior anticancer therapy need to have recovered to baseline level (except residual alopecia) or ≤ Grade 1 (neurotoxicity ≤ Grade 2 acceptable). Eastern Cooperative Oncology Group (ECOG) performance status score (PS) 0 ~ 1. Expected survival ≥ 12 weeks. Female subjects or male subjects of childbearing potential must take effective contraceptive measures from the time of signing the informed consent form to 30 days after the last dose of GFH925, or to 60 days after the last dose of cetuximab. Female subjects of childbearing potential should have a negative blood pregnancy test within 7 days (inclusive) prior to initiation of study treatment. The investigators deem the subject able to communicate well, attend regular follow-up visits, and complete the study according to the protocol. Exclusion Criteria: Significant cardiovascular system disease. Subjects with unstable brain metastases diagnosed by investigators. Significant gastrointestinal diseases, such as intractable hiccup, nausea, vomiting, severe gastrointestinal ulcers, cirrhosis, active gastrointestinal bleeding, or other diseases that affect swallowing tablets or significantly affect oral drug absorption; subjects with severe portal hypertension caused by the presence of Budd-Chiari syndrome or portal emboli in subjects with liver cancer also need to be excluded. Presence of serious acute or chronic infections. Pregnant or lactating women. Known allergy to the study drug or any component of its formulation. Other conditions that the investigators consider inappropriate for participation in this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bingo Min
Phone
+86 512 6956 6088
Email
bingo.min@innoventbio.com
Facility Information:
Facility Name
Guangdong Provincial People's Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Long Yi Wu, doctor
Phone
+86 20-8382 1484
Email
syylwu@live.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations

We'll reach out to this number within 24 hrs